Evidence map›Paper›PMID 27242892›Full record

ReviewFrontiers in genetics2016

Regulation of the Telomerase Reverse Transcriptase Subunit through Epigenetic Mechanisms.

Kayla A Lewis, Trygve O Tollefsbol

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 125 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Telomerase-Mediated Anti-Ageing Interventions.Sub-cellular biochemistry · 2024
    Review
  17. Review
  18. Review
  19. Role of telomere length in human carcinogenesis (Review).International journal of oncology · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kayla A LewisDepartment of Biology, University of Alabama at Birmingham, Birmingham AL, USA.
Trygve O TollefsbolDepartment of Biology, University of Alabama at Birmingham, BirminghamAL, USA; Comprehensive Center for Healthy Aging, University of Alabama at Birmingham, BirminghamAL, USA; Comprehensive Cancer Center, University of Alabama at Birmingham, BirminghamAL, USA; Nutrition Obesity Research Center, University of Alabama at Birmingham, BirminghamAL, USA; Comprehensive Diabetes Center, University of Alabama at Birmingham, BirminghamAL, USA.
University of Alabama at Birmingham · US

Funding

University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
Combinatorial epigenetic-based prevention of breast cancerR01CA178441 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TOLLEFSBOL, TRYGVE O · 2014 to 2025
$3.2M
NCI NIH HHS R01 CA178441NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

Chromosome-shortening is characteristic of normal cells, and is known as the end replication problem. Telomerase is the enzyme responsible for extending the ends of the chromosomes in de novo synthesis, and occurs in germ cells as well as most malignant cancers. There are three subunits of telomerase: human telomerase RNA (hTERC), human telomerase associated protein (hTEP1), or dyskerin, and human telomerase reverse transcriptase (hTERT). hTERC and hTEP1 are constitutively expressed, so the enzymatic activity of telomerase is dependent on the transcription of hTERT. DNA methylation, histone methylation, and histone acetylation are basic epigenetic regulations involved in the expression of hTERT. Non-coding RNA can also serve as a form of epigenetic control of hTERT. This epigenetic-based regulation of hTERT is important in providing a mechanism for reversibility of hTERT control in various biological states. These include embryonic down-regulation of hTERT contributing to aging and the upregulation of hTERT playing a critical role in over 90% of cancers. Normal human somatic cells have a non-methylated/hypomethylated CpG island within the hTERT promoter region, while telomerase-positive cells paradoxically have at least a partially methylated promoter region that is opposite to the normal roles of DNA methylation. Histone acetylation of H3K9 within the promoter region is associated with an open chromatin state such that transcription machinery has the space to form. Histone methylation of hTERT has varied control of the gene, however. Mono- and dimethylation of H3K9 within the promoter region indicate silent euchromatin, while a trimethylated H3K9 enhances gene transcription. Non-coding RNAs can target epigenetic-modifying enzymes, as well as transcription factors involved in the control of hTERT. An epigenetics diet that can affect the epigenome of cancer cells is a recent fascination that has received much attention. By combining portions of this diet with epigenome-altering treatments, it is possible to selectively regulate the epigenetic control of hTERT and its expression.

Indexed as

DNA methylationepigeneticshistone acetylationhistone methylationhuman telomerase reverse transcriptase (hTERT)non-coding RNA

Identifiers

PMID27242892
PMCPMC4860561
OpenAlexW2346202690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.